Bergqvist, Joel http://orcid.org/0000-0003-3170-904X
Andersson, Anders
Schiöler, Linus
Olin, Anna-Carin
Murgia, Nicola
Bove, Mogens
Janson, Christer
Abramson, Michael J.
Leynaert, Bénédicte
Nowak, Dennis
Franklin, Karl A.
PIN, Isabelle
Storaas, Torgeir
Schlünssen, Vivi
Heinrich, Joachim
Hellgren, Johan
Funding for this research was provided by:
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (-)
ALF Agreement relating to the research and education of doctors (ALF) (-)
Göteborgs Läkaresällskap (-, -)
Article History
Received: 22 December 2019
Accepted: 30 January 2020
First Online: 11 February 2020
Compliance with ethical standards
:
: JB, AA, LS, MB, CJ, BL, DN, KAF, TS, VS, JHEI, and JHEL: no financial or intellectual conflicts of interest. ACO: inventor of the PExA method, board member and chairholder of PExA AB. Disclosures have not influenced work on the current submitted manuscript. NM: grants from GSK, personal fees from ASTRA ZENECA, grants and personal fees from CHIESI, and personal fees from MENARINI, outside the submitted work. No financial or intellectual conflicts of interest regarding the content of this manuscript. MJA: grants from Pfizer, grants from Boehringer-Ingelheim, and personal fees from Sanofi, outside the submitted work. No financial or intellectual conflicts of interest regarding the content of this manuscript. IP: Travel and presentation fees from NOVARTIS and ASTRA ZENECA. Travel fees from GSK. No financial or intellectual conflicts of interest regarding the content of this manuscript.
: The study was approved by the regional ethics committee in Uppsala, Dnr 1999/313 and 2010/068.